Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells

Hiroshi Takano, Ise Tomoko, Minoru Nomoto, Ken Kato, Tadashi Murakami, Haruki Ohmori, Toshihiro Imamura, Gunji Nagatani, Tatsuro Okamoto, Ryo Ohta, Manabu Furukawa, Kazunori Shibao, Hiroto Izumi, Michihiko Kuwano, Kimitoshi Kohno

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have previously shown that the DNA topoisomerase IIα (topo IIα) gene is down-regulated in VP16/VM26-resistant cells at the transcriptional level. To determine the DNA elements responsible for down-regulation, the transcriptional activities of luciferase reporter constructs containing various lengths of the promoter sequences were investigated by transient transfection of two resistant cell lines, KB/VP2 and KB/VM4. The transcriptional activities of the full-length promoter (-295 to +85) and of three deletion constructs (-197, -154 and -74 to +85) were significantly down-regulated in resistant cells. In contrast, the transcriptional activity of the minimal promoter (-20 to +85) in resistant cells was similar to that in parental KB cells. Furthermore, introduction of a mutation in ICE1 abolished the down-regulation of the topo IIα promoter activity in drug-resistant cells. In vivo footprinting analysis of topo IIα gene promoter revealed several specific protein-binding sites, a GC box, ICE1, ICE2 and ICE3. In vivo footprinting analysis also identified a cluster of hypersensitive sites. However, there was no marked difference in protein-binding sites between parental and resistant cells. To confirm our previous results, we have established the VP16-resistant cell lines T12-VP1 and T12-VP2 from T12 cells derived from human bladder cancer T24 cells stably transfected with the chloramphenicol acetyltransferase reporter gene driven by the topo IIα gene promoter. The expression of topo IIα was down-regulated in both cell lines. We also found that CAT gene expression was significantly decreased to one-fifth of that in T12 parental cells. These results suggest that the expression of the topo IIα gene requires the binding of multiple factors to the core promoter and is down-regulated at the transcriptional level, probably through binding of a negative factor to ICE1 in drug-resistant cells.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalAnti-Cancer Drug Design
Volume14
Issue number2
StatePublished - Apr 1 1999

Fingerprint

Type II DNA Topoisomerase
Functional analysis
Structural analysis
Genes
Pharmaceutical Preparations
Cells
Binding Sites
Protein Binding
Cell Line
Chloramphenicol O-Acetyltransferase
Down-Regulation
Luciferases
Gene expression
KB Cells
Reporter Genes
Urinary Bladder Neoplasms
Transfection
DNA
Gene Expression
Mutation

Keywords

  • DNA topoisomerase IIα
  • Inverted CCAAT element (ICE)
  • Resistant cells
  • Transcription

ASJC Scopus subject areas

  • Biochemistry
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Takano, H., Tomoko, I., Nomoto, M., Kato, K., Murakami, T., Ohmori, H., ... Kohno, K. (1999). Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells. Anti-Cancer Drug Design, 14(2), 87-92.

Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells. / Takano, Hiroshi; Tomoko, Ise; Nomoto, Minoru; Kato, Ken; Murakami, Tadashi; Ohmori, Haruki; Imamura, Toshihiro; Nagatani, Gunji; Okamoto, Tatsuro; Ohta, Ryo; Furukawa, Manabu; Shibao, Kazunori; Izumi, Hiroto; Kuwano, Michihiko; Kohno, Kimitoshi.

In: Anti-Cancer Drug Design, Vol. 14, No. 2, 01.04.1999, p. 87-92.

Research output: Contribution to journalArticle

Takano, H, Tomoko, I, Nomoto, M, Kato, K, Murakami, T, Ohmori, H, Imamura, T, Nagatani, G, Okamoto, T, Ohta, R, Furukawa, M, Shibao, K, Izumi, H, Kuwano, M & Kohno, K 1999, 'Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells', Anti-Cancer Drug Design, vol. 14, no. 2, pp. 87-92.
Takano, Hiroshi ; Tomoko, Ise ; Nomoto, Minoru ; Kato, Ken ; Murakami, Tadashi ; Ohmori, Haruki ; Imamura, Toshihiro ; Nagatani, Gunji ; Okamoto, Tatsuro ; Ohta, Ryo ; Furukawa, Manabu ; Shibao, Kazunori ; Izumi, Hiroto ; Kuwano, Michihiko ; Kohno, Kimitoshi. / Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells. In: Anti-Cancer Drug Design. 1999 ; Vol. 14, No. 2. pp. 87-92.
@article{e8ea06cbe8c14d67bfad4e629380ef71,
title = "Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells",
abstract = "We have previously shown that the DNA topoisomerase IIα (topo IIα) gene is down-regulated in VP16/VM26-resistant cells at the transcriptional level. To determine the DNA elements responsible for down-regulation, the transcriptional activities of luciferase reporter constructs containing various lengths of the promoter sequences were investigated by transient transfection of two resistant cell lines, KB/VP2 and KB/VM4. The transcriptional activities of the full-length promoter (-295 to +85) and of three deletion constructs (-197, -154 and -74 to +85) were significantly down-regulated in resistant cells. In contrast, the transcriptional activity of the minimal promoter (-20 to +85) in resistant cells was similar to that in parental KB cells. Furthermore, introduction of a mutation in ICE1 abolished the down-regulation of the topo IIα promoter activity in drug-resistant cells. In vivo footprinting analysis of topo IIα gene promoter revealed several specific protein-binding sites, a GC box, ICE1, ICE2 and ICE3. In vivo footprinting analysis also identified a cluster of hypersensitive sites. However, there was no marked difference in protein-binding sites between parental and resistant cells. To confirm our previous results, we have established the VP16-resistant cell lines T12-VP1 and T12-VP2 from T12 cells derived from human bladder cancer T24 cells stably transfected with the chloramphenicol acetyltransferase reporter gene driven by the topo IIα gene promoter. The expression of topo IIα was down-regulated in both cell lines. We also found that CAT gene expression was significantly decreased to one-fifth of that in T12 parental cells. These results suggest that the expression of the topo IIα gene requires the binding of multiple factors to the core promoter and is down-regulated at the transcriptional level, probably through binding of a negative factor to ICE1 in drug-resistant cells.",
keywords = "DNA topoisomerase IIα, Inverted CCAAT element (ICE), Resistant cells, Transcription",
author = "Hiroshi Takano and Ise Tomoko and Minoru Nomoto and Ken Kato and Tadashi Murakami and Haruki Ohmori and Toshihiro Imamura and Gunji Nagatani and Tatsuro Okamoto and Ryo Ohta and Manabu Furukawa and Kazunori Shibao and Hiroto Izumi and Michihiko Kuwano and Kimitoshi Kohno",
year = "1999",
month = "4",
day = "1",
language = "English (US)",
volume = "14",
pages = "87--92",
journal = "Anti-Cancer Drug Design",
issn = "0266-9536",
publisher = "Cognizant Communication Corporation",
number = "2",

}

TY - JOUR

T1 - Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells

AU - Takano, Hiroshi

AU - Tomoko, Ise

AU - Nomoto, Minoru

AU - Kato, Ken

AU - Murakami, Tadashi

AU - Ohmori, Haruki

AU - Imamura, Toshihiro

AU - Nagatani, Gunji

AU - Okamoto, Tatsuro

AU - Ohta, Ryo

AU - Furukawa, Manabu

AU - Shibao, Kazunori

AU - Izumi, Hiroto

AU - Kuwano, Michihiko

AU - Kohno, Kimitoshi

PY - 1999/4/1

Y1 - 1999/4/1

N2 - We have previously shown that the DNA topoisomerase IIα (topo IIα) gene is down-regulated in VP16/VM26-resistant cells at the transcriptional level. To determine the DNA elements responsible for down-regulation, the transcriptional activities of luciferase reporter constructs containing various lengths of the promoter sequences were investigated by transient transfection of two resistant cell lines, KB/VP2 and KB/VM4. The transcriptional activities of the full-length promoter (-295 to +85) and of three deletion constructs (-197, -154 and -74 to +85) were significantly down-regulated in resistant cells. In contrast, the transcriptional activity of the minimal promoter (-20 to +85) in resistant cells was similar to that in parental KB cells. Furthermore, introduction of a mutation in ICE1 abolished the down-regulation of the topo IIα promoter activity in drug-resistant cells. In vivo footprinting analysis of topo IIα gene promoter revealed several specific protein-binding sites, a GC box, ICE1, ICE2 and ICE3. In vivo footprinting analysis also identified a cluster of hypersensitive sites. However, there was no marked difference in protein-binding sites between parental and resistant cells. To confirm our previous results, we have established the VP16-resistant cell lines T12-VP1 and T12-VP2 from T12 cells derived from human bladder cancer T24 cells stably transfected with the chloramphenicol acetyltransferase reporter gene driven by the topo IIα gene promoter. The expression of topo IIα was down-regulated in both cell lines. We also found that CAT gene expression was significantly decreased to one-fifth of that in T12 parental cells. These results suggest that the expression of the topo IIα gene requires the binding of multiple factors to the core promoter and is down-regulated at the transcriptional level, probably through binding of a negative factor to ICE1 in drug-resistant cells.

AB - We have previously shown that the DNA topoisomerase IIα (topo IIα) gene is down-regulated in VP16/VM26-resistant cells at the transcriptional level. To determine the DNA elements responsible for down-regulation, the transcriptional activities of luciferase reporter constructs containing various lengths of the promoter sequences were investigated by transient transfection of two resistant cell lines, KB/VP2 and KB/VM4. The transcriptional activities of the full-length promoter (-295 to +85) and of three deletion constructs (-197, -154 and -74 to +85) were significantly down-regulated in resistant cells. In contrast, the transcriptional activity of the minimal promoter (-20 to +85) in resistant cells was similar to that in parental KB cells. Furthermore, introduction of a mutation in ICE1 abolished the down-regulation of the topo IIα promoter activity in drug-resistant cells. In vivo footprinting analysis of topo IIα gene promoter revealed several specific protein-binding sites, a GC box, ICE1, ICE2 and ICE3. In vivo footprinting analysis also identified a cluster of hypersensitive sites. However, there was no marked difference in protein-binding sites between parental and resistant cells. To confirm our previous results, we have established the VP16-resistant cell lines T12-VP1 and T12-VP2 from T12 cells derived from human bladder cancer T24 cells stably transfected with the chloramphenicol acetyltransferase reporter gene driven by the topo IIα gene promoter. The expression of topo IIα was down-regulated in both cell lines. We also found that CAT gene expression was significantly decreased to one-fifth of that in T12 parental cells. These results suggest that the expression of the topo IIα gene requires the binding of multiple factors to the core promoter and is down-regulated at the transcriptional level, probably through binding of a negative factor to ICE1 in drug-resistant cells.

KW - DNA topoisomerase IIα

KW - Inverted CCAAT element (ICE)

KW - Resistant cells

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=0344258383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344258383&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 87

EP - 92

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

SN - 0266-9536

IS - 2

ER -